CD274 and esophageal squamous cell carcinoma: Consistent with this, in the present study, serplulimab combined with chemotherapy reduced risk of death by 32% compared with chemotherapy alone in patients with PD-L1-positive (CPS ≥ 1), advanced ESCC.